<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768713</url>
  </required_header>
  <id_info>
    <org_study_id>M1703</org_study_id>
    <nct_id>NCT03768713</nct_id>
  </id_info>
  <brief_title>Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Suvorexant (Belsomra®) on Sympathetic Neural Activity and Baroreflex Function in Patients With Chronic Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan Technological University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Michigan Technological University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of Suvorexant on sympathetic nerve activity and
      baroreflex function in subject with chronic insomnia. The investigator's central hypothesis
      is that Suvorexant will reduce sympathetic nerve activity and improve baroreflex function
      when compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will utilize a randomized, double-blind, placebo-controlled experimental approach
      to determine the effects of 8-wk treatment with Suvorexant (Belsomra®) on sympathetic nerve
      activity and baroreflex function in male and female subjects with chronic insomnia. The study
      will utilize established techniques for assessing sleep (polysomnography), blood pressure
      (sphygmomanometer and beat-to-beat finger plethysmography), and peripheral sympathetic nerve
      activity (microneurography). The study will stratify enrollment based upon both age and sex
      (i.e., male vs. female) because these two covariates are known to influence sympathetic nerve
      activity and baroreflex function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sympathetic nerve activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Direct recordings of muscle sympathetic nerve activity from the peroneal nerve using a microelectrode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baroreflex sensitivity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The linear relationship between changes in beat-to-beat diastolic arterial pressure and changes in sympathetic nerve activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sympathetic reactivity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change in muscle sympathetic nerve activity during a cold pressor test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home sleep quality: Wrist actigraphy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Wrist actigraphy will be used to to determine the quality of sleep, with a primary focus on sleep efficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory sleep quality: Polysomnography</measure>
    <time_frame>8 week</time_frame>
    <description>Polysomnography will be used to determine the quality of sleep, with a primary focus on sleep efficiency.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Chronic Insomnia</condition>
  <arm_group>
    <arm_group_label>Drug (Suvorexant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg of Placebo daily (taken orally ~1 hour before bedtime)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.</description>
    <arm_group_label>Drug (Suvorexant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum 3 months of clinically diagnosed insomnia

          -  Body mass index ≤35 kg/m2

          -  Insomnia Severity Index (ISI) &gt; 14 arbitrary units (i.e., moderate-to-severe insomnia)

          -  Pittsburgh Sleep Quality Index (PSQI) &gt; 5 arbitrary units

          -  Pre-menopausal women must have regular menstrual cycles (~26-30 day cycles) and will
             be scheduled for microneurography 2-7 days after menstruation to consistently test
             during the early follicular phase (or low-hormone phase in women on contraceptives)

        Exclusion Criteria:

          -  Current or prior treatment of Suvorexant.

          -  Obstructive sleep apnea defined as an apnea-hypopnea index &gt; 15 using an FDA approved
             home sleep apnea screening devices as used in routine clinical practice.

          -  Participants without evidence of clinically significant obstructive sleep apnea on the
             screening test will undergo an overnight in-laboratory polysomnography to confirm
             absence of sleep apnea (apnea-hypopnea index of ≥ 10 episodes per hour) and to exclude
             other sleep disorders (e.g. periodic limb movement arousal index of ≥ 5 episodes per
             hour)

          -  Circadian rhythm sleep disorders

          -  History of meeting DSM-V criteria of major psychiatric disorder

          -  Have been clinically-diagnosed with diabetes, cardiovascular disease, or any other
             unstable or serious medical condition.

          -  Current, or use within past month, of psychoactive (other than stable treatment with
             antidepressant), hypnotic, stimulant or analgesic medication (except occasional
             non-narcotic analgesics), beta blockers, or alpha blockers

          -  Shift work or other types of self-imposed irregular sleep schedules

          -  Habitual smoking (6 or more cigarettes per week)

          -  Habitual alcohol consumption (more than 2 alcoholic drinks per day)

          -  Breastfeeding or pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William H Cooke, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Technological University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Babak Mokhlesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Tikkanen (Michigan Tech Location)</last_name>
    <phone>906-487-2711</phone>
    <email>altikkan@mtu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Eikeland (U Chicago Location)</last_name>
    <phone>773-834-5797</phone>
    <email>insomniastudy@bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babak Mokhlesi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Technological University</name>
      <address>
        <city>Houghton</city>
        <state>Michigan</state>
        <zip>49931</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William H Cooke, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

